---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056284"
form_type: "8-K"
ticker: "LNSR"
cik: "0001320350"
company_name: "LENSAR, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:06:12.882856+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LENSAR Q1 revenue $10.6M (+28% YoY); net loss narrows to $2.2M

## Summary
- Total revenue $10.6M for Q1 2024, up 28% YoY; net loss $2.2M ($0.19 per share) vs $4.3M ($0.40) loss in Q1 2023.
- Worldwide procedure volume increased 25% to 39,486; U.S. procedure volume up 23%. Installed base of ALLY systems reached 65.
- U.S. procedure share grew 1.5% sequentially from Q4 2023, the highest single-quarter gain since ALLY launch; total share up 4.3% since launch.
- Adjusted EBITDA loss improved to $1.3M from $1.8M; SG&A flat at $6.8M, R&D down 12% to $1.4M.

## SEC filing metadata
- accession: 0000950170-24-056284
- form_type: 8-K
- ticker: LNSR
- cik: 0001320350
- company_name: LENSAR, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1320350/000095017024056284/0000950170-24-056284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1320350/000095017024056284/lnsr-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056284
- JSON: https://secwatch.observer/filing/0000950170-24-056284.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056284.txt

## Key facts
- Earnings Releases
  LENSAR, Inc. reported quarter ended March 31, 2024 results: revenue $10.6 million, net income $2.2 million, EPS ($0.19) per common share.
  - Period: quarter ended March 31, 2024
  - Revenue: $10.6 million
  - Net income: $2.2 million
  - EPS: ($0.19) per common share
  - Result: reported results
  source text: and staff as well as better surgical outcomes for patients, allowed us to deliver continued 20%+ revenue growth in the first quarter of 2024. Total revenue for the quarter was $10.6 million, up 28% over the first quarter of 2023. Moreover, procedure volume grew by 23% in the U.S., our largest market and the only country where ALLY is currently marketed,” said Nick
  evidence_url: https://www.sec.gov/Archives/edgar/data/1320350/000095017024056284/0000950170-24-056284-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.